Hyderabad: Cohance Lifesciences has announced thatthe United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at our API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh. The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations. "We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets," the company stated in a BSE filing. Read also:Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio Cohance Lifesciences is a technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. The company has over 100 active projects and a pipeline of late-stage molecules. Read also:Advent International to purchase significant stake in Suven Pharma, plans merger with Cohance Lifesciences
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!